Suppression of kshv lytic replication and primary effusion lymphoma by selective rnf5 inhibition

HIGHLIGHTS

• who: Xiaojuan Li and collaborators from the Institute of Human Virology, Zhongshan School of Medicine, Yat-Sen University, Guangzhou, China have published the research: Suppression of KSHV lytic replication and primary effusion lymphoma by selective RNF5 inhibition, in the Journal: (JOURNAL) of October/18,/2022
• what: The study showed that RNF5 inhibition suppresses PEL growth with two types of increased Ephrin type-A receptors, EphA3 and EphA4, and decreased activation of the ERK and Akt pathways, downregulating the expression of multiple cellular pathways and KSHV lytic viral genes, providing a novel choice for PEL therapy . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.